直接口服抗凝药治疗期间急诊凝血评估的局限与对策
正常PT/aPTT特异性不足,正常TT敏感性仅26%;采用试剂特异性cutoff可提高特异性和敏感性,但阿哌沙班无法确定cutoff。
要点
- 正常PT和aPTT特异性不足,不能安全排除DOAC抗凝作用。
- 正常TT对达比加群特异性100%但敏感性仅26%,会排除多数 eligible 患者。
- 试剂特异性PT/aPTT cutoff对利伐沙班和达比加群可提供>95%特异性并优化敏感性。
核心结论
- 正常常规凝血试验结果不适用于指导急诊治疗决策。
- 试剂特异性cutoff可确保高特异性并优化利伐沙班和达比加群患者的敏感性。
研究设计与样本
- 检测PT、aPTT、TT、DOAC特异性测定及液相色谱-串联质谱。
- 计算识别DOAC浓度<30 ng/mL的敏感性和特异性,并用ROC分析定义试剂特异性cutoff。
主要发现
- 利伐沙班/PT:特异性77%,敏感性94%。
- 阿哌沙班/PT:特异性13%,敏感性94%。
- 达比加群/aPTT:特异性49%,敏感性91%。
- 正常TT对达比加群特异性100%,敏感性26%。
- 试剂特异性PT和aPTT cutoff提供>95%特异性;特异性TT cutoff使达比加群敏感性提高至84%。
关键数值与推荐
- DOAC浓度<30 ng/mL为识别目标。
- 利伐沙班/PT正常值:特异性77%,敏感性94%。
- 阿哌沙班/PT正常值:特异性13%,敏感性94%。
- 达比加群/aPTT正常值:特异性49%,敏感性91%。
- 正常TT对达比加群:特异性100%,敏感性26%。
临床怎么用
- 急诊决策不应仅依赖正常PT/aPTT排除DOAC抗凝。
- 对利伐沙班和达比加群可使用试剂特异性cutoff辅助决策。
- 阿哌沙班无法建立cutoff,需谨慎解读常规凝血结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In patients receiving direct oral anticoagulants (DOACs), emergency treatment like thrombolysis for acute ischemic stroke is complicated by insufficient availability of DOAC-specific coagulation tests. Conflicting recommendations have been published concerning the use of global coagulation assays for ruling out relevant DOAC-induced anticoagulation. METHODS: Four hundred eighty-one samples from 96 DOAC-treated patients were tested using prothrombin time (PT), activated partial thromboplastin time (aPTT) and thrombin time (TT), DOAC-specific assays (anti-Xa activity, diluted TT), and liquid chromatography-tandem mass spectrometry. Sensitivity and specificity of test results to identify DOAC concentrations <30 ng/mL were calculated. Receiver operating characteristic analyses were used to define reagent-specific cutoff values. RESULTS: Normal PT and aPTT provide insufficient specificity to safely identify DOAC concentrations <30 ng/mL (rivaroxaban/PT: specificity, 77%/sensitivity, 94%; apixaban/PT: specificity, 13%/sensitivity, 94%, dabigatran/aPTT: specificity, 49%/sensitivity, 91%). Normal TT was 100% specific for dabigatran, but sensitivity was 26%. In contrast, reagent-specific PT and aPTT cutoffs provided >95% specificity and a specific TT cutoff enhanced sensitivity for dabigatran to 84%. For apixaban, no cutoffs could be established. CONCLUSIONS: Even if highly DOAC-reactive reagents are used, normal results of global coagulation tests are not suited to guide emergency treatment: whereas normal PT and aPTT lack specificity to rule out DOAC-induced anticoagulation, the low sensitivity of normal TT excludes the majority of eligible patients from treatment. However, reagent-specific cutoffs for global coagulation tests ensure high specificity and optimize sensitivity for safe emergency decision making in rivaroxaban- and dabigatran-treated patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT02371044 and NCT02371070.
引用
- Ebner M, Birschmann I, Peter A, et al. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions. Stroke. 2017. PMID: 28775134. doi:10.1161/STROKEAHA.117.017981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。